The global demand for systemic mastocytosis treatment is slated to grow at a moderate CAGR of around 5% to5.6% CAGR during the forecast period from 2022 to 2032. Growth in the market is driven by rising prevalence of systemic mastocytosis across the globe and development of new treatment drugs.
| Report Attribute | Details |
| Systemic Mastocytosis Treatment Market Projected Growth Rate (2022-2032) | 5% - 5.6% CAGR |
Systemic mastocytosis is a rare disease or blood disorder generally caused by KIT gene mutation that results in too many mast cells building up in a patient's body. The condition often leads to excessive accumulation of mast cells in skin, bone marrow, liver, digestive tract and several other body organs. This in turn causes several mild to severe symptoms.
There are various subtypes of systemic mastocytosis including indolent systemic mastocytosis, aggressive systemic mastocytosis, systemic mastocytosis associated with hematologic non-mast cell lineage disorder, and mast cell leukemia, depending on the indication. Among these indolent systemic mastocytosis is the mildest form of systemic mastocytosis while mast cell leukemia, aggressive systemic mastocytosis, and systemic mastocytosis associated with hematologic non-mast cell lineage disorder are severe ones. The severe forms of systemic mastocytosis can significantly reduce the life span of patients.
Although there is no permanent treatment currently available for this condition, various drugs such as antihistamines, proton pump inhibitors, steroids, tyrosine kinase inhibitors, epinephrine, and mast-cell stabilizers are being used for relieving the symptoms. Rising consumption of these drug classes for treating and minimizing the symptoms as well as improving the quality of life is a major force behind the expansion of systemic mastocytosis treatment market.
Leading market players are increasingly investing in research and development activities to develop and evaluate possible treatment options that can effectively eliminate the symptoms of systemic mastocytosis.
The swift expansion of systemic mastocytosis treatment market is attributed to the rising prevalence of systemic mastocytosis worldwide, growing awareness among people about systemic mastocytosis, its diagnosis and treatment, advancements in treatments options, and increasing government support.
Systemic mastocytosis treatments such as antihistamines, tyrosine kinase inhibitors, proton pump inhibitors, Epinephrine, and Steroids have become ideal options for treating and relieving multiple symptoms of systemic mastocytosis. They are being increasingly consumed by patients suffering from systemic mastocytosis to improve their quality of life. This factor is likely to provide a strong push to the growth of systemic mastocytosis treatment market during the forecast period.
Similarly, various government and non-government organizations are putting various efforts to reduce the global burden of systemic mastocytosis. They are launching various awareness programs to educate people about this condition, its diagnosis and treatment. This will continue to boost market growth in the forthcoming years.
Additionally, rising investments in research and development by key market players coupled with increasing novel drug launches and approvals is expected to further expand the systemic mastocytosis treatment market size during the assessment period.
Despite a positive growth trajectory, the global mastocytosis treatment market is facing various challenges that are slowing down its growth. Some of these factors are the low diagnostic rates, lack of awareness about the condition and availability of its treatment, rising costs of treatment, and side effects associated with various treatment drugs.
With rising prevalence of systemic mastocytosis, presence of leading market players, and availability of several treatment drugs, North America spearheaded by the U.S., is expected to continue its dominance in the global systemic mastocytosis treatment market during the assessment period.
The U.S. is home to some of the major pharmaceutical and biotechnological companies of the world. These companies are continuously striving to launch innovative treatment solutions for rare diseases like systemic mastocytosis. This is emerging as a key factor in boosting the growth of systemic mastocytosis market across the region.
According to Future Market Insights, Europe will continue to remain the second most lucrative market on account of higher patient pool, growing healthcare awareness among people, and rising adoption of systemic mastocytosis treatment for minimizing and eradicating various symptoms.
Moreover, rapid expansion of healthcare industry coupled with increase in drug research and development activities across countries like the United Kingdom and France is positively impacting the market growth.
Some of the key participants present in the global systemic mastocytosis treatment market include Merck & Co. Inc., Bausch Health Companies Inc., Sanofi S.A., Pfizer Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Novartis AG, Johnson & Johnson, Bayer AG, Mallinckrodt Pharmaceuticals, EPI Health, LLC, and Kaleo Inc.
These market players are vigorously investing in research and development for introducing novel treatments for systemic mastocytosis. Besides this, they have adopted various growth strategies such as acquisitions, partnerships, price reduction, new product launches and approvals, strengthening of distribution channels, and launch of awareness campaigns to gain a competitive edge in the market.
| Report Attribute | Details |
| Growth Rate | CAGR of 5% - 5.6% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Drug Class:
By Indication:
By Route of Administration:
By Distribution Channel:
By Region:
FMI projects the global systemic mastocytosis treatment market to expand at around 5% to 5.6% CAGR over the assessment period from 2022 to 2032.
North America is expected to remain the most lucrative market for systemic mastocytosis treatment during the forecast period.
Merck & Co. Inc., Bausch Health Companies Inc., Sanofi S.A., Pfizer Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., and Novartis AG are some prominent players operating in the systemic mastocytosis treatment market.
Explore Similar Insights
Systemic Mastocytosis Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
